We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genetic Link Found Between Gut Disorders and Alzheimer's Disease

By LabMedica International staff writers
Posted on 02 Aug 2022

Alzheimer’s disease (AD) is the most prevalent form of dementia, characterized by neurodegeneration and a progressive decline in cognitive ability. More...

The disorder ranks as a subject of increasing global public health importance with consequences for wide-ranging social and economic adverse impacts on sufferers, their families, and the society at large.

Several studies have reported a pattern of co-occurrence of dementia (and AD in particular) with certain gastrointestinal tract (GIT) disorders, microbiota, dysbiosis or medications commonly used in the treatment of peptic ulcer disease (PUD). The available evidence, thus, suggests comorbidity or some forms of association between AD and GIT disorders, although it is not clear whether GIT traits are risks for AD or vice versa.

Medical Scientists at the Edith Cowan University, (Perth, Australia) in a new study set out to find out genetic associations underlying this observed association between the gut and AD. They analyzed genetic data from 15 large genome studies, most involving more than 400,000 people, containing information from AD and gut disorders. They also looked at the biological pathways in which these genes involved in both disorders acted, and found an overrepresentation of lipid-related and immune system-related pathways.

The investigators reported that they found certain genes were associated with having both AD and certain gut disorders, such as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), gastritis-duodenitis, irritable bowel syndrome, and diverticulosis. Although they s found significant genetic overlap and correlation between Alzheimer’s and some gastrointestinal disorders, they did not find evidence for a causal association.

Cross-trait meta-analysis identified several loci shared by AD and GIT disorders (GERD and PUD) including PDE4B, BRINP3, ATG16L1, SEMA3F, HLA-DRA, SCARA3, MTSS2, PHB, and TOMM40. Colocalization and gene-based analyses reinforced these loci. Pathway-based analyses demonstrated significant enrichment of lipid metabolism, autoimmunity, lipase inhibitors, PD-1 signaling, and statin mechanisms, among others, for AD and GIT traits.

The study provided genetic insights into the long-standing debate and the observed relationship of AD with GIT disorders, implicating shared genetic susceptibility. The findings support a significant risk increasing (but non-causal) genetic association between AD and GIT traits (GERD, PUD, PGM, gastritis-duodenitis, IBS, and diverticular disease). Also, the scientists identified genomic regions and genes, shared by AD and GIT disorders that may potentially be targeted for further investigation, particularly, the PDE4B gene (or its subtypes) which has shown promise in inflammatory diseases.

Simon Laws, PhD, the director of the Centre for Precision Health and senior author of the study, said, “That although the study did not find that gut disorders caused AD or vice versa, the findings were immensely valuable. These findings provide further evidence to support the concept of the ‘gut-brain’ axis, a two-way link between the brain’s cognitive and emotional centers, and the functioning of the intestines.”

The authors concluded that their study also underscores the importance of lipid homoeostasis and the potential relevance of statins and lipase inhibitors in AD, GIT disorders or their comorbidity. The study was published on July 18, 2022 in the journal Communications Biology.

Related Links:
Edith Cowan University 


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.